NeoSync may consider device loan support for proposed research efforts conducted and sponsored by investigators. If you are interested in conducting an Investigator Initiated Trial using NeoSync devices, please contact us.
CAUTION: NEST® is an investigational device and limited by federal (United States) law to Investigational Use
A sham controlled randomized 52-patient clinical study of the sTMS technology was recently published in BMC Psychiatry (2014, 14:13), showing that sTMS showed a significantly greater percentage reduction in depression severity compared to sham (48.5% vs. 19.3%, respectively; p = 0.001).
NeoSync has completed a 200 patient randomized, multi-center, sham-controlled clinical trial with investigators from 17 leading academic and private psychiatric institutions. The results among treatment-resistant depressed patients compared favorably to the results seen from prior TMS clinical studies in comparable patient populations. In addition, the NeoSync NEST® showed a clean safety and tolerability profile, with no device-related major adverse events.
Please click on the link to view all clinical trials listed through www.clinicaltrials.gov.